236 related articles for article (PubMed ID: 27465204)
21. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Wolfson LJ; Gibbert J; Wirth D; Diel R
Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
[No Abstract] [Full Text] [Related]
23. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
[TBL] [Abstract][Full Text] [Related]
24. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Lessem E; Cox V; Furin J
Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
[No Abstract] [Full Text] [Related]
25. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
Millard J; Rimmer S; Nimmo C; O'Donnell M
Emerg Infect Dis; 2023 May; 29(5):1081-1084. PubMed ID: 37081529
[TBL] [Abstract][Full Text] [Related]
26. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
Guglielmetti L; Hewison C; Avaliani Z; Hughes J; Kiria N; Lomtadze N; Ndjeka N; Setkina S; Shabangu A; Sikhondze W; Skrahina A; Veziris N; Furin J
Int J Tuberc Lung Dis; 2017 Feb; 21(2):167-174. PubMed ID: 28234080
[TBL] [Abstract][Full Text] [Related]
27. Bedaquiline and delamanid in tuberculosis.
Esposito S; Bianchini S; Blasi F
Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
[TBL] [Abstract][Full Text] [Related]
28. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.
Nasiri MJ; Zangiabadian M; Arabpour E; Amini S; Khalili F; Centis R; D'Ambrosio L; Denholm JT; Schaaf HS; van den Boom M; Kurhasani X; Dalcolmo MP; Al-Abri S; Chakaya J; Alffenaar JW; Akkerman O; Silva DR; Muňoz-Torrico M; Seaworth B; Pontali E; Saderi L; Tiberi S; Zumla A; Migliori GB; Sotgiu G
Int J Infect Dis; 2022 Nov; 124 Suppl 1(Suppl 1):S90-S103. PubMed ID: 35245659
[TBL] [Abstract][Full Text] [Related]
29. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
[No Abstract] [Full Text] [Related]
30. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
Hafkin J; Hittel N; Martin A; Gupta R
Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253
[No Abstract] [Full Text] [Related]
31. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
[TBL] [Abstract][Full Text] [Related]
32. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
Hu M; Zheng C; Gao F
Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
[TBL] [Abstract][Full Text] [Related]
33. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
[TBL] [Abstract][Full Text] [Related]
34. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
[TBL] [Abstract][Full Text] [Related]
35. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.
Li Y; Sun F; Zhang W
Drug Dev Res; 2019 Feb; 80(1):98-105. PubMed ID: 30548290
[TBL] [Abstract][Full Text] [Related]
36. Early mortality during rifampicin-resistant TB treatment.
Mohr-Holland E; Daniels J; Reuter A; Rodriguez CA; Mitnick C; Kock Y; Cox V; Furin J; Cox H
Int J Tuberc Lung Dis; 2022 Feb; 26(2):150-157. PubMed ID: 35086627
[TBL] [Abstract][Full Text] [Related]
37. Delamanid in the treatment of multidrug-resistant tuberculosis.
Gupta R; Wells CD; Hittel N; Hafkin J; Geiter LJ
Int J Tuberc Lung Dis; 2016 Dec; 20(12):33-37. PubMed ID: 28240570
[TBL] [Abstract][Full Text] [Related]
38. Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.
Furin J; Brigden G; Lessem E; Rich M; Vaughan L; Lynch S
Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26885674
[TBL] [Abstract][Full Text] [Related]
39. Management of drug resistantTB in patients with HIV co-infection.
Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
[TBL] [Abstract][Full Text] [Related]
40. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
